TO WHAT EXTENT ARE BASELINE CHARACTERISTICS IN BIOLOGIC-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS ASSOCIATED WITH ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AT WEEK 24 OF GUSELKUMAB TREATMENT: A POST HOC ANALYSIS OF THE PHASE IIIB COSMOS CLINICAL TRIAL

被引：0
|
作者：
Tillett, W. [1 ]
Ohrndorf, S. [2 ]
Ramirez, J. [3 ]
Neuhold, M. [4 ]
Wapenaar, R. [5 ]
Theander, E. [6 ]
Contre, C. [7 ]
Sharaf, M. [8 ]
Shawi, M. [9 ]
Vis, M. [10 ]
机构：
[1] Univ Bath, Royal Natl Hosp Rheumat Dis, Bath, Avon, England
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Hosp Univ Clin, Barcelona, Spain
[4] Janssen Cilag, Zug, Switzerland
[5] Janssen Cilag BV, Breda, Netherlands
[6] Janssen Cilag, Solna, Sweden
[7] Janssen Cilag, Issy Les Moulineaux, France
[8] Janssen Cilag, Dubai, U Arab Emirates
[9] Janssen Global Serv LLC, Horsham, PA USA
[10] Erasmus MC, Univ Med Ctr, Rotterdam, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.2624
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1051
引用
收藏
页码：844 / 845
页数：2
相关论文
共 27 条
  • [21] BASELINE FACTORS ASSOCIATED WITH LUPUS FLARES: A POST-HOC ANALYSIS OF PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS ENROLLED IN A 48 WEEK PHASE II RANDOMIZED CLINICAL TRIAL
    Lindsay, L.
    Mao, H. A.
    Cheng, J. E.
    Chuo, C. Y.
    Jones, N.
    Cascino, M. D.
    Tuckwell, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 648 - 648
  • [22] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated With Guselkumab: Posthoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Ritchlin, Christopher
    Mease, Philip
    Boehncke, Wolf-Henning
    Tesser, John
    Allard-Chamard, Hugues
    Chakravarty, Soumya
    Rampakakis, Emmanouil
    Shawi, May
    Schiopu, Elena
    Merola, Joseph
    McInnes, Iain
    Deodhar, Atul
    JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 29 - 30
  • [23] LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Gladman, D. D.
    Starr, M.
    Ranza, R.
    Bravo Perdomo, A. M.
    Strauss, M.
    Shawi, M.
    Han, C.
    Rampakakis, E.
    Ostor, A. Andrew
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1765 - 1765
  • [24] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
    Gladman, Dafna
    Starr, Michael
    Ranza, Roberto
    Perdomo, Ana-Maria Bravo
    Strauss, Marcie
    Shawi, May
    Han, Chenglong
    Rampakakis, Emmanouil
    Ostor, Andrew
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4175 - 4178
  • [25] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis
    Gladman, Dafna
    Starr, Michael
    Ranza, Roberto
    Perdomo, Ana
    Strauss, Marcie
    Shawi, May
    Han, Chenglong
    Rampakakis, Emmanouil
    Ostor, Andrew
    Mease, Philip
    JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 79 - 79
  • [26] Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-na_ive Patients With Psoriatic Arthritis (PsA)
    Gladman, Dafna D.
    Starr, Michael
    Ranza, Roberto
    Bravo, Ana-Maria
    Strauss, Marcie
    Shawi, May
    Han, Chenglong
    Rampakakis, Emmanouil
    Ostor, Andrew
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB189 - AB189
  • [27] Comparison of ixekizumab with ustekinumab in patients with baseline PASI>15 and/or at-least 3previous-non-biologic-therapies-treatment-failures: 24-week post-hoc-analysis from a randomized trial (IXORA-S; NCT02561806)
    Burkhardt, N.
    Wilhelm, S.
    Riedl, E.
    Kelin, K.
    Henneges, C.
    Smith, S. D.
    Shumack, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 41 - 41
123